Ischemix Enrolls First Patient In Phase 2a Trial To Prevent Contrast-Induced Acute Kidney Injury

MAYNARD, Mass.--(BUSINESS WIRE)--Ischemix, Inc., a pharmaceutical company developing a portfolio of cytoprotective compounds to address serious diseases, is pleased to announce that it has successfully enrolled the first patient in a Phase 2a trial of its lead compound to prevent contrast-induced acute kidney injury (“CI-AKI”) in acute coronary syndrome patients undergoing coronary angiography (the “CARIN” trial). The Company’s lead compound, CMX-2043, is a chemically-modified, naturally-occurring molecule with an excellent safety profile that has demonstrated efficacy in a prior human clinical trial.

Help employers find you! Check out all the jobs and post your resume.